This is a list of pharmaceutical companies that are developing psychedelic drugs and/or related drugs such as entactogens, other hallucinogens, or non-hallucinogenic variants (e.g., psychoplastogens) for potential medical use. This list also includes individual drug candidates and compounds of psychedelic pharmaceutical companies.
Modern AbbVie – bretisilocin (GM-2505, 5-F-MET; acquired from Gilgamesh Pharmaceuticals) Akome Biotech – AKO-001 (DMT combination), AKO-002 (psilocybin combination), AKO-003 (ketamine combination), AKO-004 (DMT combination) Alexander Shulgin Research Institute (ASRI) – ASR-2001 (2CB-5PrO), ASR-3001 (5-MeO-iPALT) Algernon NeuroScience – DMT (AP-188) Alvarius Pharmaceuticals – 5-MeO-DMT (mebufotenin) Amandala Neuro – psilocin (ELE-101) Apex Labs – psilocybin (APEX-52/90) Arcadia Medicine – non-racemic MDMA (AM-1002), AM-1004, AM-1006 Ariadne Bio (subsidiary of Negev Labs) – AB-300 Atai Life Sciences (merged with Beckley Psytech) – DMT (VLS-01), (R)-MDMA (EMP-01), ibogaine (IBX-210, DMX-1002), EGX-121, inidascamine (RL-007), EGX-A, EGX-B, arketamine (PCN-101) AtaiBeckley (merger of Atai Life Sciences and Beckley Psytech; acquired by Eli Lilly and Company) – 5-MeO-DMT (mebufotenin, BPL-003), DMT (VLS-01), (R)-MDMA (EMP-01) Awakn Life Sciences (acquired by Solvonis Therapeutics) – ketamine (AWKN-001), MDMA (midomafetamine), esketamine (AWKN-002) Beckley Psytech (merged with Atai Life Sciences) – 5-MeO-DMT (mebufotenin, BPL-003), psilocin (ELE-01) BetterLife Pharma – 2-bromo-LSD (BETR-001, TD-0148A) Biomind Labs – DMT (BMND-01–03), DMT (Triptax), 5-MeO-DMT (mebufotenin, BMND-05/08), BMND007 (DMT or 5-MeO-DMT combination), mescaline (BMND-04/06/09), ibogaine Bright Minds Biosciences – BMB-101, BMB-105, BMB-201, BMB-202, Pharm-136 CaaMTech – CT-4201 (psilocin prodrug), TN-001 (via spinout Transneural Therapeutics), TN-002 (via spinout Transneural Therapeutics) Ceruvia Lifesciences – psilocybin (SYNP-101), 2-bromo-LSD (NYPRG-101) Clearmind Medicine – MEAI (CMND-100), 2-FDCK, 3-MMC Clexio Biosciences – esketamine (CLE-100) Compass Pathways – psilocybin (COMP360) Definium Therapeutics (Mind Medicine, MindMed) – LSD (DT120, MM120), (R)-MDMA (MM402), zolunicant (18-MC, MM110), ketanserin (neutralizer), MDMA (midomafetamine), lys-MDA Delix Therapeutics – ibogainalog, tabernanthalog (DLX-007), zalsupindole (DLX-001, AAZ-A-154), DLX-159, DLX-2270, DLX-0002700, JRT DemeRx – ibogaine (IBX-210), noribogaine (DMX-1001) Diamond Therapeutics – psilocybin Eleusis (acquired by Beckley Psytech) – psilocybin (ELE-101, ELE-Psilo), ELE-01 (a phenethylamine), 2C-iBu (ELE-02), ketamine (ELE-Ket) EmpathBio – (R)-MDMA (EMP-01) Engrail Therapeutics – ENX-105, ENX-205 Entheon Biomedical – DMT (EBRX-101) Entropy Neurodynamics – psilocybin (TRP-8802), psilocin (TRP-8803) Enveric Biosciences – EB-002 (EB-373; psilocin prodrug), EB-003 Equulus Therapeutics – EQL-101 (ibogaine analogue) Filament Health – psilocybin (PEX010) Freedom Biosciences – ketamine/temsirolimus (FREE001) GH Research – 5-MeO-DMT (mebufotenin, GH001–003) Gilgamesh Pharmaceuticals – bretisilocin (GM-2505, 5-F-MET), blixeprodil ((R)-4-FDCK, GM-1020), GM-3009 (an oxa-iboga), GM-5022, GM-2040, oxa-noribogaine, 4-allyl-6-oxa-noribogainalog Helus Pharma (Cybin) – deupsilocin (psilocin-d10; HLP003, CYB003), deudimethyltryptamine (DMT-d10; HLP004, CYB004), HLP005 (CYB005), 2C-T-36 (CYB210010), DMT (SPL026), SPL028 (D2-DMT) Incannex Healthcare – psilocybin (PSX-001) Johnson & Johnson – esketamine (Spravato), ITI-1549 (via acquiring Intra-Cellular Therapies) Journey Colab – mescaline (JOUR-5700) Ketabon – oral prolonged-release ketamine (KET01) Küleon Bioscience (Psilosterics) – KB-128 Lophora – LPH-5 ((S)-2C-TFM-3PIP), LPH-48 Lucid Psycheceuticals – Lucid-PSYCH (Lucid-201) Lusaris Therapeutics – 5-MeO-DMT (mebufotenin) MiHKAL – lys-MDA, SDA, SDMA MindBio Therapeutics – LSD (MB-22001) Mindset Pharma (acquired by Otsuka Pharmaceutical) – MSP-1014 (psilocin prodrug), MSP-2020, MSP-4018, MSP-4019, MSP-4020 Mindstate Design Labs – 5-MeO-MiPT (MSD-001), 5-MeO-MiPT combinations (e.g., MSD-101, MSD-201, etc.) MSICS Pharma – psilocybin (MSX-06) Multidisciplinary Association for Psychedelic Studies (MAPS) – MDMA (midomafetamine) MycoMedica Life Sciences – psilocybin (MLS101) Mydecine – psilocybin (MYCO-001/003), MYCO-006, MYCO-007, MYCO-002, MYCO-004, MYCO-005 Negev Labs – HBL20016 (5-MeS-6-F-DMT), HBL20017 (4-F-5-MeS-DMT) Neurala Biosciences – DMT/harmala alkaloids (NBX-100, NBX-200) Neurocentrx Pharma – misuse-deterrant oral ketamine (NRCx-201) Ninnion Therapeutics – NIN-S119 (a tryptamine) Nobilis Therapeutics – xenon (NBTX-001) NRx Pharmaceuticals – ketamine (NRX-100) Otsuka Pharmaceutical – acquired Mindset Pharma and Transcend Therapeutics and of all their drug candidates PharmAla Biotech – racemic MDMA (LaNeo), non-racemic MDMA (ALA-002), MBDB, APA-01 (PharmAla-1) Pilz Bioscience – psilocin (PLZ-1015), baeocystin (PLZ-1019), norpsilocin (PLZ-1017) Psilera – DMT, PSIL-001, PSIL-002, PSIL-006, PSIL-020, PSIL-025, 4-AcO-DMT PsyBio Therapeutics – psilocybin (PB-1818), norbaeocystin Psychae Therapeutics – DMT/β-carboline Psyence Biomedical (Psyence BioMed) – [natural] psilocybin Reconnect Labs – dimethyltryptamine/harmine (RE01), sublingual 5-MeO-DMT (mebufotenin; RE02) Relmada Therapeutics – psilocybin (REL-P11) Reset Pharma – psilocybin (RSTP-1000) Resilient Pharmaceuticals (Lykos Pharmaceuticals, MAPS Public Benefit Corporation) – MDMA (midomafetamine) Reunion Neuroscience (Field Trip Health) – luvesilocin (RE104, FT104, 4-GO-DiPT), RE109 (FT109, 4-GO-DMT), RE245 Revive Therapeutics – psilocybin (PSY-0.1–0.6) Scottsdale Research Institute – psilocybin-containing mushrooms Seaport Therapeutics – SPT-348 (2-bromo-LSD prodrug) Seelos Therapeutics – ketamine (Ereska, PMI-100, PMI-150, SLS-002, TUR-002) Sensorium Therapeutics – SNTX-2643 (SENS-01; kanna derivative) Small Pharma (acquired by Cybin/Helus Pharma) – DMT (SPL026), SPL028 (D2-DMT) Solvonis Therapeutics – ketamine (SVN-001), esketamine (SVN-002), SVN-114 (SVN-SDN-14 series), SVN-015 Soneira Bio – ibogaine/magnesium (SON-001) Tactogen – MDMA/citalopram, TACT411, TACT523, TACT833, TACT908, 1Z2MAP1O, 1ZP2MA Tasman Therapeutics (spinout of Douglas Pharmaceuticals) – oral extended-release ketamine (R-107) Terran Biosciences – eplivanserin/volinanserin (trip killer/blocker) Transcend Therapeutics (acquired by Otsuka Pharmaceutical) – methylone (MDMC, TSND-201) Transneural Therapeutics (a spinout of CaaMTech) – TN-001, TN-002 Tryp Therapeutics – psilocybin (PFN, TRP-8802–8804, TRYP-0082) Usona Institute – psilocybin, 5-MeO-DMT (mebufotenin), bufotenin (5-HO-DMT) Xylo (Psylo) – XYL-1001 (PSYLO-1001), XYL-1002 (PSYLO-1002), XYL-3001 (PSYLO-3001), XYL-4001 (PSYLO-4001), XYL-5001 (PSYLO-5001)
Historical Bristol-Myers Company (Bristol Laboratories) – (R)-Ariadne ((R)-4C-DOM, BL-3912A, Dimoxamine) Dow Chemical Company – DOM (K-61,082), DOET Merck – MDMA, mescaline Sandoz – LSD (LSD-25, lysergide, Delysid), psilocybin (CY-39, Indocybin), psilocin (CX-59), ethocybin (CEY-19), 4-HO-DET (ethocin; CZ-74), 4-HO-AMT (MP-14), 4-Me-AMT (MP-809), others Smith, Kline & French – MDA (SKF-5, Amphedoxamine), 3-APBT (SKF-6678) Soviet Union – α-methyltryptamine (AMT, Indopan) Upjohn – α-ethyltryptamine (AET, etryptamine, Monase)
See also List of investigational hallucinogens and entactogens List of psychedelic chemists List of psychedelic news and media organizations List of psychedelic conferences List of psychedelic drugs Psychedelic Alpha
References
External links Psychedelic Companies Directory - Psychedelic Alpha Psychedelics Drug Development Tracker - Psychedelic Alpha Psychedelic Drug Development Tracker Bullseye (Q1 2026) - Psychedelic Alpha (PDF)